Paris-based Cure51 raises €15 million to develop first-in-class treatments from exceptional cancer survivors

Published on March 20, 2024

Cure51, a techbio company seeking to unlock the biological mechanisms responsible for exceptional survivors among cancer patients, announced that it has successfully raised €15 million in a seed funding round led by Sofinnova Partners. Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog. The funding…

This content is for members only. Visit the site and log in/register to read.

The post Paris-based Cure51 raises €15 million to develop first-in-class treatments from exceptional cancer survivors appeared first on EU-Startups.

Continue reading on website
Other news

The Buying Power of Social Security Was Downgraded by 36% – Here’s What it Means for You

March 20, 2024
For retirees, disability survivors, and people with disabilities, Social Security is a vital safety net. Nearly 67 million people, or around 1 in 5, receive Social Security benefits. According to...

Research Shows Pursuing Your Hobbies Benefits Your Business, Too. Here's How to Make More Time for Them.

March 20, 2024
Discover the brain and business benefits of pursuing your hobbies.